EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before.

In 2021, Abdul Latif Jameel Health announced a partnership to become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.

Butterfly Network created the world’s only handheld, single-probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ. Its mission is to democratize medical imaging and contribute to the aspiration of global health equity by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected—including for the 4.7 billion people around the world lacking access to ultrasound.

In 2021, Abdul Latif Jameel Health entered a strategic distribution partnership to bring Butterfly iQ+ ultrasound device to a potential 2 billion people across the Middle East, North Africa, Turkey & India.

Cyberdyne Inc. of Japan are world leading innovative pioneers of AI-robotic solutions including the Hybrid Assisted Limb (HAL)®

Abdul Latif Jameel was the first to introduce HAL®and ‘Cybernics Therapy’ into Saudi Arabia at the Abdul Latif Jameel Rehabilitation Hospital, Jeddah, teaching spinal injury patients to regain use of their limbs. The relationship has since expanded to include the GCC with the Hospital as a regional training center.

Japanese immunology, biochemistry and healthtech pioneer Cellspect is developing breakthrough highly portable point-of-care-testing (POCT) devices that can address the needs of dispersed populations.

In 2019, Abdul Latif Jameel began a collaboration with Cellspect to bring these low-cost POCT devices to developing markets.

Japanese innovative investment platform, JOMDD, specializes in investing and commercializing transformative new technologies in medical device development.

In early 2020, Abdul Latif Jameel and JOMDD announced their investment/incubator partnership to bring innovative Japanese medical device technology to developing markets

AVNeo (Aortic Valve Neocuspidization) is a standardized revolutionary procedural technique used to reconstruct the aortic heart valve using the patient’s own pericardial tissue.

Partnering with JOMDD and the Saudi Arabian Ministry of Health, Abdul Latif Jameel Health is introducing this pioneering life saving procedure into Saudi Arabia. Latest data showed the 10-year survival rate was 85.9% for AVNeo compared to less than 80% for alternative procedures.